Evotec SE (EVO)

Nasdaq: EVO · Pharmaceutical Preparations · Hamburg, DE · filing with the SEC since 2007

Full chart Alerts Compare

Grade5.1

◀ Past 6.5● Present 5.6▶ Future 3.0

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2024, as filed

Revenue€797M+2.0%

Net income-€196M-133.7%

Earnings per share€-1.11-136.2%

Operating cash flow€18.2M-50.0%

Cash€306M-40.0%

Debt€288M-34.2%

Shareholders’ equity€953M-14.9%

Shares, diluted177.3M+0.2%

Return on equity-20.6%

The recordfrom its filings

Filings in 202628

Newest filingNov 5 · 6-K

Annual reportApr 8, 2026

Quarterly reportn/a

Next report due20-F by Apr 30

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents granted25

Filer categoryLarge accelerated filer

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

192021222324

As filed, in EUR. Nothing here is a forecast.

News

Nov 5, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Oct 15, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Oct 14, 2026 · SEC EDGAR · Form SCHEDULE 13D/A

Activist holder update, amended

Open the filing on sec.gov

Oct 14, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Sep 29, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Sep 9, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Aug 13, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Jul 14, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Jun 30, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

Jun 17, 2026 · SEC EDGAR · Form 6-K

Interim report, foreign filer

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Evotec SE is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Hamburg, DE.

Newest on the record

Interim report, foreign filer on Nov 5. Before it, interim report, foreign filer on Oct 15.

What is due next

The 20-F for the period to Dec 31, 2026, due by Apr 30, 2027.

About EVO

Evotec SE is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Hamburg, DE. In its latest annual figures on file, for the fiscal year ended 2024-12-31, it reported revenue of EUR 797 million and a loss of EUR 196 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersHamburg, DE

Business modelProduct business

ExchangeNasdaq, OTC

Filing since2007

Fiscal year endsDec 31

SEC number (CIK)1412558

Peers on fileLLY, KROS, CORT, UTHR

Who runs it

Financial performance

In fiscal 2024 Evotec SE’s revenue was €797.0 million, up 2.0% from €781.4 million the year before. It made a net loss of €196.1 million.

Annual report, filed Apr 8, 2026.

Financial statements

The grade

Evotec SE grades 5.1 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Eight of the nine metrics are read as filed and one is an SI estimate, each with its reasoning.

◀ Past6.5

● Present5.6

▶ Future3.0

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton EVO · research, not advice